Peginterferon Alfa-2a Injection
Generic name: Pronounced as (peg in ter feer' on)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 06/15/2016
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I know about STORAGE and DISPOSAL of this medication?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
IMPORTANT WARNING
Peginterferon alfa-2a may cause or worsen the following conditions, which may be serious or cause death: infections; mental illness including depression, mood and behavior problems, or thoughts of hurting or killing yourself; starting to use street drugs again if you used them in the past; ischemic disorders (conditions in which there is poor blood supply to an area of the body) such as angina (chest pain), heart attack, stroke, or colitis (inflammation of the bowels); and autoimmune disorders (conditions in which the immune system attacks one or more parts of the body) that may affect the blood, joints, kidneys, liver, lungs, muscles, skin, or thyroid gland. Tell your doctor if you have an infection; or if you have or have ever had an autoimmune disease; atherosclerosis (narrowing of the blood vessels from fatty deposits); cancer; chest pain; colitis; diabetes; heart attack; high blood pressure; high cholesterol; HIV (human immunodeficiency virus) or AIDS (acquired immunodeficiency syndrome); irregular heartbeat; mental illness including depression, anxiety, or thinking about or trying to kill yourself; liver disease other than hepatitis B or C; or heart, kidney, lung or thyroid disease. Also tell your doctor if you drink or have ever drunk large amounts of alcohol, or if you use or have ever used street drugs or have overused prescription medications. If you experience any of the following symptoms, call your doctor immediately: bloody diarrhea or bowel movements; stomach pain, tenderness or swelling; chest pain; irregular heartbeat; weakness; loss of coordination; numbness; changes in your mood or behavior; depression; irritability; anxiety; thoughts of killing or hurting yourself; hallucinating (seeing things or hearing voices that do not exist); frenzied or abnormally excited mood; loss of contact with reality; aggressive behavior; difficulty breathing; fever, chills, cough, sore throat, or other signs of infection; coughing up yellow or pink mucus; burning or pain when urinating, or urinating more often; unusual bleeding or bruising; dark-colored urine; light colored bowel movements; extreme tiredness; yellowing of the skin or eyes; severe muscle or joint pain; or worsening of an autoimmune disease.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to peginterferon alfa-2a.
Your doctor and pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with peginterferon alfa-2a and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.
Talk to your doctor about the risks of using peginterferon alfa-2a.
Why is this medication prescribed?
Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is also used to treat chronic hepatitis B infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is in a class of medications called interferons. Peginterferon is a combination of interferon and polyethylene glycol, which helps the interferon stay active in your body for a longer period of time. Peginterferon works by decreasing the amount of hepatitis C virus (HCV) or hepatitis B virus (HBV) in the body. Peginterferon alfa-2a may not cure hepatitis C or hepatitis B or prevent you from developing complications of hepatitis C or hepatitis B such as cirrhosis (scarring) of the liver, liver failure, or liver cancer. Peginterferon alfa-2a may not prevent the spread of hepatitis C or hepatitis B to other people.
How should this medicine be used?
Peginterferon alfa-2a comes as a solution (liquid) in a vial, a prefilled syringe, and a disposable autoinjector to inject subcutaneously (into the fatty layer just under the skin). It is usually injected once a week, on the same day of the week, and at around the same time of day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use peginterferon alfa-2a exactly as directed. Do not use more or less of this medication or use it more often than prescribed by your doctor.
Your doctor will probably start you on an average dose of peginterferon alfa-2a. Your doctor may decrease your dose if you experience serious side effects of the medication. Be sure to tell your doctor how you are feeling during your treatment and ask your doctor or pharmacist if you have questions about the amount of medication you should take.
Continue to use peginterferon alfa-2a even if you feel well. Do not stop using peginterferon alfa-2a without talking to your doctor.
Only use the brand and type of interferon that your doctor prescribed. Do not use another brand of interferon or switch between peginterferon alfa-2a in vials, prefilled syringes, and disposable autoinjectors without talking to your doctor. If you switch to a different brand or type of interferon, your dose may need to be changed.
You can inject peginterferon alfa-2a yourself or have a friend or relative give you the injections. Before you use peginterferon alfa-2a for the first time, you and the person who will be giving the injections should read the manufacturer's information for the patient that comes with it. Ask your doctor or pharmacist to show you or the person who will be injecting the medication how to inject it. If another person will be injecting the medication for you, be sure that he or she knows how to avoid accidental needlesticks to prevent the spread of hepatitis.
You can inject peginterferon alfa-2a anywhere on your stomach or thighs, except your navel (belly button) and waistline. Use a different spot for each injection. Do not use the same injection spot two times in a row. Do not inject peginterferon alfa-2a into an area where the skin is sore, red, bruised, scarred, infected, or abnormal in any way.
If you do not receive the full prescribed dose because of a problem (such as leakage around the injection site), call your doctor.
Never reuse syringes, needles, or vials of peginterferon alfa-2a. Dispose of used needles and syringes in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.
Before you use peginterferon alfa-2a, look at the solution in the vial, prefilled syringe, or autoinjector closely. Do not shake vials, syringes, or autoinjectors containing peginterferon alfa-2a. The medication should be clear and free of floating particles. Check the vial or syringe to make sure there are no leaks and check the expiration date. Do not use the solution if it is expired, discolored, cloudy, contains particles, or is in a leaky vial or syringe. Use a new solution, and show the damaged or expired one to your doctor or pharmacist.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before using peginterferon alfa-2a,
-
tell your doctor and pharmacist if you are allergic to peginterferon alfa-2a, other alpha interferons, any other medications, benzyl alcohol, or polyethylene glycol (PEG). Ask your doctor if you are not sure if a medication you are allergic to is an alpha interferon.
-
tell your doctor if you have ever received interferon alfa injection for treating hepatitis C infection.
-
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain medications for HIV or AIDS such as abacavir (Ziagen, in Epzicom, in Trizivir), didanosine (ddI or Videx), emtricitabine (Emtriva, in Truvada), lamivudine (Epivir, in Combivir, in Epzicom, in Trizivir), stavudine (Zerit), tenofovir (Viread, in Truvada), zalcitabine (HIVID), and zidovudine (Retrovir, in Combivir, in Trizivir); methadone (Dolophine, Methadose); mexiletine (Mexitil); naproxen (Aleve, Anaprox, Naprosyn, others); riluzole (Rilutek); tacrine (Cognex); telbivudine (Tyzeka); and theophylline (TheoDur, others). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with peginterferon alfa-2a, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
-
tell your doctor or pharmacist if you have ever had an organ transplant (surgery to replace an organ in the body). Also tell your doctor if you have or have ever had any of the conditions mentioned in the IMPORTANT WARNING section or any of the following: anemia (red blood cells do not bring enough oxygen to other parts of the body), or problems with your eyes or pancreas.
-
tell your doctor if you are pregnant, plan to become pregnant or are breastfeeding. Peginterferon alfa-2a may harm the fetus or cause you to miscarry (lose your baby). Talk to your doctor about using birth control while you are taking this medication. You should not breastfeed while you are taking this medication.
-
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking peginterferon alfa-2a.
-
you should know that peginterferon alfa-2a may make you dizzy, confused, or drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
-
do not drink alcohol while you are taking peginterferon alfa-2a. Alcohol can make your liver disease worse.
-
you should know that you may experience flu-like symptoms such as headache, fever, chills, tiredness, muscle aches, and joint pain during your treatment with peginterferon alfa-2a. If these symptoms are bothersome, ask your doctor if you should take an over-the-counter pain and fever reducer before you inject each dose of peginterferon alfa-2a. You may want to inject peginterferon alfa-2a at bedtime so that you can sleep through the symptoms.
What special dietary instructions should I follow?
Drink plenty of fluids while you are taking this medication.
What should I do if I forget a dose?
If you remember the missed dose no longer than 2 days after you were scheduled to inject it, inject the missed dose as soon as you remember it. Then inject your next dose on your regularly scheduled day the following week. If more than 2 days have passed since the day you were scheduled to inject the medication, ask your doctor or pharmacist what you should do. Do not use a double dose or use more than one dose in 1 week to make up for a missed dose.
What side effects can this medication cause?
-
Peginterferon alfa-2a may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
bruising, pain, redness, swelling, or irritation in the place you injected peginterferon alfa-2a
-
upset stomach
-
vomiting
-
heartburn
-
dry mouth
-
loss of appetite
-
weight loss
-
diarrhea
-
dry or itchy skin
-
hair loss
-
difficulty falling asleep or staying asleep
-
tiredness
-
weakness
-
difficulty concentrating or remembering
-
sweating
-
dizziness
-
-
Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them, or those listed in the IMPORTANT WARNING section or the SPECIAL PRECAUTIONS section, call your doctor immediately:
-
blurred vision ,vision changes, or loss of vision
-
lower back pain
-
rash
-
hives
-
swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
-
difficulty swallowing
-
hoarseness
-
-
Peginterferon alfa-2a may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it in the refrigerator, but do not freeze it. Do not leave peginterferon alfa-2a outside of the refrigerator for more than 24 hours (1 day). Keep peginterferon alfa-2a away from light.
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
If the victim has not collapsed, call the doctor who prescribed this medication. The doctor may want to order lab tests.
Symptoms of overdose may include the following:
-
tiredness
-
unusual bleeding or bruising
-
fever, sore throat, chills, cough, or other signs of infection
What OTHER INFORMATION should I know?
Do not let anyone else use your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Leflunomide | Leflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Leflunomide. |
Aminophylline | Aminophylline The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a. |
Anagrelide | Anagrelide The metabolism of Anagrelide can be decreased when combined with Peginterferon alfa-2a. |
Cilostazol | Cilostazol The metabolism of Cilostazol can be decreased when combined with Peginterferon alfa-2a. |
Clopidogrel | Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Peginterferon alfa-2a. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Peginterferon alfa-2a. |
Mycophenolate | Mycophenolate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mycophenolic acid. |
Polyethylene glycol-electrolyte solution (PEG-ES) | Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a. |
Prednisone | Prednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisone. |
Ranitidine | Ranitidine The metabolism of Ranitidine can be decreased when combined with Peginterferon alfa-2a. |
Tacrolimus | Tacrolimus Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2a. |
Tizanidine | Tizanidine The metabolism of Tizanidine can be decreased when combined with Peginterferon alfa-2a. |
Triamcinolone | Triamcinolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Triamcinolone. |
Zolmitriptan | Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2a. |
Interferon Beta-1b Injection | Interferon Beta-1b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b. |
Interferon Gamma-1b Injection | Interferon Gamma-1b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon gamma-1b. |
Methylprednisolone Injection | Methylprednisolone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methylprednisolone. |
Metoclopramide Injection | Metoclopramide Injection The metabolism of Metoclopramide can be decreased when combined with Peginterferon alfa-2a. |
Zidovudine Injection | Zidovudine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine. |
Cyclosporine | Cyclosporine Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine. |
Enoxaparin Injection | Enoxaparin Injection The risk or severity of bleeding can be increased when Enoxaparin is combined with Peginterferon alfa-2a. |
Olanzapine | Olanzapine The metabolism of Olanzapine can be decreased when combined with Peginterferon alfa-2a. |
Alosetron | Alosetron The metabolism of Alosetron can be decreased when combined with Peginterferon alfa-2a. |
Hydroxychloroquine | Hydroxychloroquine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxychloroquine. |
Temozolomide | Temozolomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temozolomide. |
Anakinra | Anakinra The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Anakinra. |
Linezolid | Linezolid The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Linezolid. |
Pentosan Polysulfate | Pentosan Polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Peginterferon alfa-2a. |
Etanercept Injection | Etanercept Injection The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a. |
Sirolimus | Sirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sirolimus. |
Epirubicin | Epirubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Epirubicin. |
Adalimumab Injection | Adalimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Adalimumab. |
Glatiramer Injection | Glatiramer Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Glatiramer. |
Polyethylene Glycol 3350 | Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a. |
Frovatriptan | Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Peginterferon alfa-2a. |
Darbepoetin Alfa Injection | Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Peginterferon alfa-2a. |
Infliximab Injection | Infliximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab. |
Duloxetine | Duloxetine The metabolism of Duloxetine can be decreased when combined with Peginterferon alfa-2a. |
Cinacalcet | Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Peginterferon alfa-2a. |
Natalizumab Injection | Natalizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab. |
Erlotinib | Erlotinib The metabolism of Erlotinib can be decreased when combined with Peginterferon alfa-2a. |
Palifermin | Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2a. |
Entecavir | Entecavir The metabolism of Entecavir can be decreased when combined with Peginterferon alfa-2a. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon alfa-2b. |
Ramelteon | Ramelteon The metabolism of Ramelteon can be decreased when combined with Peginterferon alfa-2a. |
Abatacept Injection | Abatacept Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Abatacept. |
Rasagiline | Rasagiline The metabolism of Rasagiline can be decreased when combined with Peginterferon alfa-2a. |
Imatinib | Imatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Imatinib. |
Bevacizumab Injection | Bevacizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab. |
Bortezomib | Bortezomib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bortezomib. |
Clofarabine Injection | Clofarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clofarabine. |
Hepatitis B Vaccine | Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2a. |
Influenza Vaccine, Inactivated or Recombinant | Influenza Vaccine, Inactivated or Recombinant The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a. |
Influenza Vaccine, Live Intranasal | Influenza Vaccine, Live Intranasal The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Peginterferon alfa-2a. |
Live Shingles (Zoster) Vaccine (ZVL) | Live Shingles (Zoster) Vaccine (ZVL) The risk or severity of infection can be increased when Peginterferon alfa-2a is combined with Varicella Zoster Vaccine (Live/attenuated). |
Oxaliplatin Injection | Oxaliplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin. |
Primaquine | Primaquine The metabolism of Primaquine can be decreased when combined with Peginterferon alfa-2a. |
Rituximab Injection | Rituximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab. |
Pemetrexed Injection | Pemetrexed Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pemetrexed. |
Telbivudine | Telbivudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine. |
Vorinostat | Vorinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vorinostat. |
Sorafenib | Sorafenib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sorafenib. |
Sunitinib | Sunitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sunitinib. |
Pegaptanib Injection | Pegaptanib Injection The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Peginterferon alfa-2a. |
Pegfilgrastim Injection | Pegfilgrastim Injection The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a. |
Dasatinib | Dasatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dasatinib. |
Mexiletine | Mexiletine The metabolism of Mexiletine can be decreased when combined with Peginterferon alfa-2a. |
Azacitidine Injection | Azacitidine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azacitidine. |
Temsirolimus | Temsirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temsirolimus. |
Nelarabine Injection | Nelarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nelarabine. |
Lenalidomide | Lenalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lenalidomide. |
Nilotinib | Nilotinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nilotinib. |
Bexarotene | Bexarotene The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene. |
Budesonide | Budesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Budesonide. |
Chloramphenicol Injection | Chloramphenicol Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chloramphenicol. |
Decitabine Injection | Decitabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Decitabine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Arsenic trioxide. |
Mitoxantrone Injection | Mitoxantrone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitoxantrone. |
Tretinoin | Tretinoin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tretinoin. |
Bendamustine Injection | Bendamustine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bendamustine. |
Flecainide | Flecainide The metabolism of Flecainide can be decreased when combined with Peginterferon alfa-2a. |
Certolizumab Injection | Certolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Certolizumab pegol. |
Ixabepilone Injection | Ixabepilone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixabepilone. |
Irinotecan Injection | Irinotecan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Irinotecan. |
Estramustine | Estramustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Estramustine. |
Praziquantel | Praziquantel The metabolism of Praziquantel can be decreased when combined with Peginterferon alfa-2a. |
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) | Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab. |
Dexrazoxane Injection | Dexrazoxane Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane. |
Eltrombopag | Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Peginterferon alfa-2a. |
Ibritumomab Injection | Ibritumomab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan. |
Betaxolol | Betaxolol The metabolism of Betaxolol can be decreased when combined with Peginterferon alfa-2a. |
Prasugrel | Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Peginterferon alfa-2a. |
Everolimus | Everolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Everolimus. |
Pralatrexate Injection | Pralatrexate Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pralatrexate. |
Topotecan | Topotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Topotecan. |
Golimumab Injection | Golimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Golimumab. |
Pazopanib | Pazopanib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pazopanib. |
Asenapine | Asenapine The metabolism of Asenapine can be decreased when combined with Peginterferon alfa-2a. |
Albendazole | Albendazole The metabolism of Albendazole can be decreased when combined with Peginterferon alfa-2a. |
Denosumab Injection | Denosumab Injection The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2a. |
Dabigatran | Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2a. |
Tocilizumab Injection | Tocilizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tocilizumab. |
Fingolimod | Fingolimod Peginterferon alfa-2a may increase the immunosuppressive activities of Fingolimod. |
Eribulin Injection | Eribulin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eribulin. |
Cabazitaxel Injection | Cabazitaxel Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cabazitaxel. |
Pegloticase Injection | Pegloticase Injection The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2a. |
Acetaminophen Injection | Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Peginterferon alfa-2a. |
Denileukin Diftitox Injection | Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin. |
Sipuleucel-T Injection | Sipuleucel-T Injection The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Peginterferon alfa-2a. |
Belimumab Injection | Belimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belimumab. |
Busulfan Injection | Busulfan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Busulfan. |
Roflumilast | Roflumilast Roflumilast may increase the immunosuppressive activities of Peginterferon alfa-2a. |
Cyclophosphamide Injection | Cyclophosphamide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cyclophosphamide. |
Rivaroxaban | Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Peginterferon alfa-2a. |
Ticagrelor | Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2a. |
Brentuximab Vedotin Injection | Brentuximab Vedotin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brentuximab vedotin. |
Ruxolitinib | Ruxolitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib. |
Belatacept Injection | Belatacept Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belatacept. |
Basiliximab Injection | Basiliximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab. |
Axitinib | Axitinib The metabolism of Axitinib can be decreased when combined with Peginterferon alfa-2a. |
Melphalan Injection | Melphalan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Melphalan. |
Eculizumab Injection | Eculizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eculizumab. |
Fondaparinux Injection | Fondaparinux Injection The risk or severity of bleeding can be increased when Fondaparinux is combined with Peginterferon alfa-2a. |
Pertuzumab Injection | Pertuzumab Injection The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Pertuzumab. |
Carfilzomib Injection | Carfilzomib Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carfilzomib. |
Iloprost | Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Peginterferon alfa-2a. |
Bosutinib | Bosutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bosutinib. |
Corticotropin, Repository Injection | Corticotropin, Repository Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Corticotropin. |
Teriflunomide | Teriflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teriflunomide. |
Icosapent Ethyl | Icosapent Ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2a. |
Tofacitinib | Tofacitinib Peginterferon alfa-2a may increase the immunosuppressive activities of Tofacitinib. |
Dimethyl Fumarate | Dimethyl Fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dimethyl fumarate. |
Ponatinib | Ponatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ponatinib. |
Pomalidomide | Pomalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trastuzumab emtansine. |
Apixaban | Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Peginterferon alfa-2a. |
Perampanel | Perampanel The metabolism of Perampanel can be decreased when combined with Peginterferon alfa-2a. |
Ibrutinib | Ibrutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibrutinib. |
Obinutuzumab Injection | Obinutuzumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Obinutuzumab. |
Dapagliflozin | Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Peginterferon alfa-2a. |
Apremilast | Apremilast The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Apremilast. |
Siltuximab Injection | Siltuximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siltuximab. |
Vedolizumab Injection | Vedolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vedolizumab. |
Belinostat Injection | Belinostat Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belinostat. |
Idelalisib | Idelalisib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib. |
Vorapaxar | Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Peginterferon alfa-2a. |
Edoxaban | Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Peginterferon alfa-2a. |
Peginterferon Beta-1a Injection | Peginterferon Beta-1a Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon beta-1a. |
Olaparib | Olaparib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Olaparib. |
Blinatumomab Injection | Blinatumomab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Blinatumomab. |
Tasimelteon | Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Peginterferon alfa-2a. |
Pirfenidone | Pirfenidone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pirfenidone. |
Secukinumab Injection | Secukinumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Secukinumab. |
Palbociclib | Palbociclib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Palbociclib. |
Panobinostat | Panobinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Panobinostat. |
Dinutuximab Injection | Dinutuximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dinutuximab. |
Haloperidol Injection | Haloperidol Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a. |
Prednisolone | Prednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisolone. |
Mepolizumab Injection | Mepolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mepolizumab. |
Trabectedin Injection | Trabectedin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trabectedin. |
Dexamethasone Injection | Dexamethasone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone. |
Defibrotide Injection | Defibrotide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2a. |
Ixekizumab Injection | Ixekizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixekizumab. |
Rucaparib | Rucaparib The metabolism of Rucaparib can be decreased when combined with Peginterferon alfa-2a. |
Brodalumab Injection | Brodalumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brodalumab. |
Doxepin (Insomnia) | Doxepin (Insomnia) The metabolism of Doxepin can be decreased when combined with Peginterferon alfa-2a. |
Deflazacort | Deflazacort The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Deflazacort. |
Ocrelizumab Injection | Ocrelizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ocrelizumab. |
Sarilumab Injection | Sarilumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sarilumab. |
Guselkumab Injection | Guselkumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Guselkumab. |
Enasidenib | Enasidenib The metabolism of Enasidenib can be decreased when combined with Peginterferon alfa-2a. |
Betrixaban | Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Peginterferon alfa-2a. |
Gemtuzumab Ozogamicin Injection | Gemtuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin. |
Penicillamine | Penicillamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Penicillamine. |
Baricitinib | Baricitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Baricitinib. |
Lofexidine | Lofexidine The metabolism of Lofexidine can be decreased when combined with Peginterferon alfa-2a. |
Binimetinib | Binimetinib The metabolism of Binimetinib can be decreased when combined with Peginterferon alfa-2a. |
Pegvaliase-pqpz Injection | Pegvaliase-pqpz Injection The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginterferon alfa-2a. |
Stiripentol | Stiripentol The metabolism of Stiripentol can be decreased when combined with Peginterferon alfa-2a. |
Methoxy Polyethylene Glycol-Epoetin Beta Injection | Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Peginterferon alfa-2a is combined with Methoxy polyethylene glycol-epoetin beta. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paclitaxel. |
Ravulizumab-cwvz Injection | Ravulizumab-cwvz Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ravulizumab. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Emapalumab. |
Siponimod | Siponimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siponimod. |
Acyclovir Ophthalmic | Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Peginterferon alfa-2a. |
Caplacizumab-yhdp Injection | Caplacizumab-yhdp Injection The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2a. |
Risankizumab-rzaa Injection | Risankizumab-rzaa Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Risankizumab. |
Cladribine | Cladribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cladribine. |
Triclabendazole | Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Peginterferon alfa-2a. |
Pexidartinib | Pexidartinib Peginterferon alfa-2a may increase the hepatotoxic activities of Pexidartinib. |
Istradefylline | Istradefylline The metabolism of Istradefylline can be decreased when combined with Peginterferon alfa-2a. |
Ozanimod | Ozanimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ozanimod. |
Selumetinib | Selumetinib The metabolism of Selumetinib can be decreased when combined with Peginterferon alfa-2a. |
Theophylline | Theophylline The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a. |
Indomethacin | Indomethacin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Indomethacin. |
Naproxen | Naproxen The metabolism of Naproxen can be decreased when combined with Peginterferon alfa-2a. |
Hydroxyurea | Hydroxyurea The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxyurea. |
Floxuridine | Floxuridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Floxuridine. |
Methotrexate Injection | Methotrexate Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methotrexate. |
Chlorpromazine | Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Peginterferon alfa-2a. |
Carmustine | Carmustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine. |
Procarbazine | Procarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine. |
Thioguanine | Thioguanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tioguanine. |
Trifluoperazine | Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Peginterferon alfa-2a. |
Bleomycin | Bleomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleomycin. |
Methadone | Methadone The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a. |
Maprotiline | Maprotiline The metabolism of Maprotiline can be decreased when combined with Peginterferon alfa-2a. |
Perphenazine | Perphenazine The metabolism of Perphenazine can be decreased when combined with Peginterferon alfa-2a. |
Azathioprine | Azathioprine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azathioprine. |
Sulfasalazine | Sulfasalazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sulfasalazine. |
Lomustine | Lomustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lomustine. |
Doxorubicin | Doxorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Doxorubicin. |
Cytarabine | Cytarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine. |
Mechlorethamine | Mechlorethamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mechlorethamine. |
Dactinomycin | Dactinomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dactinomycin. |
Carbamazepine | Carbamazepine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carbamazepine. |
Clonidine | Clonidine The metabolism of Clonidine can be decreased when combined with Peginterferon alfa-2a. |
Warfarin | Warfarin The metabolism of Warfarin can be decreased when combined with Peginterferon alfa-2a. |
Daunorubicin | Daunorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin. |
Digoxin | Digoxin Digoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a. |
Quinine | Quinine The metabolism of Quinine can be decreased when combined with Peginterferon alfa-2a. |
Triamterene | Triamterene The metabolism of Triamterene can be decreased when combined with Peginterferon alfa-2a. |
Sulfinpyrazone | Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2a. |
Chlorothiazide | Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Peginterferon alfa-2a. |
Amitriptyline | Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Peginterferon alfa-2a. |
Imipramine | Imipramine The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a. |
Disopyramide | Disopyramide The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a. |
Tamoxifen | Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Peginterferon alfa-2a. |
Mitomycin | Mitomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitomycin. |
Methimazole | Methimazole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methimazole. |
Propylthiouracil | Propylthiouracil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil. |
Cyclobenzaprine | Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Peginterferon alfa-2a. |
Methyclothiazide | Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2a. |
Hydrochlorothiazide | Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Peginterferon alfa-2a. |
Chlorzoxazone | Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Peginterferon alfa-2a. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The metabolism of Propranolol can be decreased when combined with Peginterferon alfa-2a. |
Mercaptopurine | Mercaptopurine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mercaptopurine. |
Allopurinol | Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Peginterferon alfa-2a. |
Fluorouracil Injection | Fluorouracil Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluorouracil. |
Colchicine | Colchicine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Colchicine. |
Dacarbazine | Dacarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dacarbazine. |
Bacillus Calmette-Guerin (BCG) Vaccine | Bacillus Calmette-Guerin (BCG) Vaccine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Peginterferon alfa-2a. |
Thiotepa Injection | Thiotepa Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thiotepa. |
Vincristine Injection | Vincristine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine. |
Dipyridamole | Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2a. |
Vinblastine | Vinblastine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinblastine. |
Thiothixene | Thiothixene The metabolism of Thiothixene can be decreased when combined with Peginterferon alfa-2a. |
Aspirin | Aspirin The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2a. |
Chlorambucil | Chlorambucil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chlorambucil. |
Nifedipine | Nifedipine The metabolism of Nifedipine can be decreased when combined with Peginterferon alfa-2a. |
Verapamil | Verapamil The metabolism of Verapamil can be decreased when combined with Peginterferon alfa-2a. |
Cisplatin Injection | Cisplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cisplatin. |
Streptozocin | Streptozocin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Streptozocin. |
Etoposide | Etoposide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Etoposide. |
Pentoxifylline | Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Peginterferon alfa-2a. |
Guanabenz | Guanabenz The metabolism of Guanabenz can be decreased when combined with Peginterferon alfa-2a. |
Pimozide | Pimozide The metabolism of Pimozide can be decreased when combined with Peginterferon alfa-2a. |
Diclofenac | Diclofenac The metabolism of Diclofenac can be decreased when combined with Peginterferon alfa-2a. |
Fluoxetine | Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Peginterferon alfa-2a. |
Interferon Alfa-2b Injection | Interferon Alfa-2b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b. |
Clozapine | Clozapine The risk or severity of neutropenia can be increased when Peginterferon alfa-2a is combined with Clozapine. |
Idarubicin | Idarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idarubicin. |
Fludarabine Injection | Fludarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fludarabine. |
Pentostatin Injection | Pentostatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pentostatin. |
Nabumetone | Nabumetone The metabolism of Nabumetone can be decreased when combined with Peginterferon alfa-2a. |
Epoetin Alfa, Injection | Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Peginterferon alfa-2a. |
Teniposide Injection | Teniposide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teniposide. |
Zolpidem | Zolpidem The metabolism of Zolpidem can be decreased when combined with Peginterferon alfa-2a. |
Fluvoxamine | Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Peginterferon alfa-2a. |
Vinorelbine Injection | Vinorelbine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinorelbine. |
Carboplatin Injection | Carboplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin. |
Ifosfamide Injection | Ifosfamide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ifosfamide. |
Pegaspargase Injection | Pegaspargase Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase. |
Ticlopidine | Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Peginterferon alfa-2a. |
Dalteparin Injection | Dalteparin Injection The risk or severity of bleeding can be increased when Dalteparin is combined with Peginterferon alfa-2a. |
Riluzole | Riluzole The metabolism of Riluzole can be decreased when combined with Peginterferon alfa-2a. |
Anastrozole | Anastrozole The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Anastrozole. |
Gemcitabine Injection | Gemcitabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemcitabine. |
Docetaxel Injection | Docetaxel Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Docetaxel. |
Clomipramine | Clomipramine The metabolism of Clomipramine can be decreased when combined with Peginterferon alfa-2a. |
Mirtazapine | Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Peginterferon alfa-2a. |
Zileuton | Zileuton The metabolism of Zileuton can be decreased when combined with Peginterferon alfa-2a. |
Carvedilol | Carvedilol The metabolism of Carvedilol can be decreased when combined with Peginterferon alfa-2a. |
Flutamide | Flutamide The metabolism of Flutamide can be decreased when combined with Peginterferon alfa-2a. |
Selegiline | Selegiline The metabolism of Selegiline can be decreased when combined with Peginterferon alfa-2a. |
Propafenone | Propafenone The metabolism of Propafenone can be decreased when combined with Peginterferon alfa-2a. |
Ropinirole | Ropinirole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ropinirole. |
Paroxetine | Paroxetine The metabolism of Paroxetine can be decreased when combined with Peginterferon alfa-2a. |
Capecitabine | Capecitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Capecitabine. |
Efavirenz | Efavirenz The metabolism of Efavirenz can be decreased when combined with Peginterferon alfa-2a. |
Trastuzumab Injection | Trastuzumab Injection Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a. |
Thalidomide | Thalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thalidomide. |
Terbinafine | Terbinafine The metabolism of Terbinafine can be decreased when combined with Peginterferon alfa-2a. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists